Brief: Olezarsen SNDA Accepted By The FDA For Priority Review
26/02/2026 12:21
Feb 26 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: OLEZARSEN SNDA ACCEPTED BY THE FDA FOR PRIORITY REVIEW FOR THE TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (SHTG) IONIS PHARMACEUTICALS INC - FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF JUNE 30, 2026 Source text: ID:nBw9CPpSPa Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors